SCHEMBL15469386

SCHEMBL15469386

Cc1ccc(C2(N)CCOc3cccnc32)cc1F

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.33
AKR1B10 O60218 1/20 0.33
AKR1C4 P17516 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
BACE1 P56817 5/20 0.32
APP P05067 3/20 0.32
PDE4B Q07343 2/20 0.31
PDE4D Q08499 2/20 0.31
RAB9A P51151 1/20 0.31
GRM4 Q14833 1/20 0.31
CTNNB1 P35222 1/20 0.31
WNT3A P56704 1/20 0.31
MAP3K14 Q99558 2/20 0.30
AKT1 P31749 1/20 0.30
AKT2 P31751 1/20 0.30
STIM1 Q13586 1/20 0.30
ORAI1 Q96D31 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15469414 1.00 TRPM8 (0.33) TRPM8AKR1B10AKR1C4AKR1C3AKR1C2
SCHEMBL15469507 0.93 PDE4B (0.32) TRPM8AKR1B10AKR1C4AKR1C3AKR1C2
SCHEMBL16418774 0.88 NOS3 (0.33) TRPM8BACE1APPRAB9AMAP3K14
SCHEMBL15469509 0.87 BACE1 (0.34) AKR1B10AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL15469511 0.85 GRM4 (0.33) TRPM8BACE1APPGRM4
SCHEMBL15469461 0.85 MAP3K14 (0.35) TRPM8RAB9AGRM4MAP3K14
SCHEMBL15467719 0.84 PDE2A (0.38) TRPM8CTNNB1WNT3AAKT1AKT2
SCHEMBL15467717 0.84 PDE2A (0.38) TRPM8CTNNB1WNT3AAKT1AKT2
SCHEMBL15469465 0.84 BACE1 (0.32) AKR1B10AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL15469480 0.84 BACE1 (0.34) AKR1B10AKR1C4AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885AKR1B10 3940/4885AKR1C4 4289/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885AKR1B10 3940/4885AKR1C4 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.